Výsledky vyhledávání - "HUININK, W. W. TEN BOKKEL"

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group

Autor: Dirix, L. Y., Tonnesen, F., Cassidy, J., Epelbaum, R., Huinink, W. W. Ten Bokkel, Pavlidis, Nicholas, Sorio, R., Gamucci, T., Wolff, I., Velde, A. Te, Lan, J., Verweij, J.

Publikováno v: European journal of cancer
European Journal of Cancer Part A

In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a63e22d5b3f7daefd9445b39d685d20f
https://doi.org/10.1016/0959-8049(96)00226-2

Zobrazit plný text záznamu

Docetaxel (TaxotereTM), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study

Autor: Sternberg, Cora N., Huinink, W. W. Ten Bokkel, Smyth, J. F., Bruntsch, V., Dirix, L. Y., Pavlidis, Nicholas, Franklin, H. R., Wanders, S., Bail, N. Le, Kaye, Stanley B.

Publikováno v: British Journal of Cancer
British journal of cancer

Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic agent for the treatment of cancer. Forty patients with bidimensionally measurable advanced adenocarcinoma of the colon were treated with docetaxel 100 mg m-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5aa067f62963feadd4184d8229722a9
https://doi.org/10.1038/bjc.1994.309

Zobrazit plný text záznamu

Phase II clinical trials with rhizoxin in breast cancer and melanoma

Autor: Hanauske, A. R., Catimel, G., Aamdal, S., Huinink, W. W. Ten Bokkel, Paridaens, R., Pavlidis, Nicholas, Kaye, Stanley B., Velde, A. Te, Wanders, J., Verweij, J.

Publikováno v: British journal of cancer

Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The purpose of our studies was to determin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4485::e744a18d14c2bb29bb126f551d14d2b5
https://gnosis.library.ucy.ac.cy/handle/7/41857

Zobrazit plný text záznamu

Multicentre phase II pharmacological evaluation of rhizoxin

Autor: McLeod, H. L., Murray, L. S., Wanders, J., Setanoians, A., Graham, M. A., Pavlidis, Nicholas, Heinrich, B., Huinink, W. W. Ten Bokkel, Wagener, D. J. Th, Aamdal, S., Verweij, J.

Publikováno v: British journal of cancer

Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines and xenograft models. Phase T evaluation found a m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4485::cd97d092f67ec5441555381c83421152
https://gnosis.library.ucy.ac.cy/handle/7/42154

Zobrazit plný text záznamu